Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$79.04 USD

79.04
640,484

-2.77 (-3.39%)

Updated Aug 5, 2024 10:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease

by Zacks Equity Research

FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

by Zacks Equity Research

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Kinjel Shah headshot

Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals

by Kinjel Shah

Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.

Astrazeneca (AZN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Jobless Claims Decreased More Than Expected

by Zacks Equity Research

Jobless Claims Decreased More Than Expected

Mark Vickery headshot

Jobless Claims Steady; Mixed Q4 for AZN, HSY and PM

by Mark Vickery

We're once again reassured that employment, on a finer week-over-week scale, is not falling off a cliff.

AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low double-digit to low teens percentage in 2024 at CER.

Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales

by Zacks Equity Research

Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.

Astrazeneca (AZN) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View

by Zacks Equity Research

Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.

Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.

Astrazeneca (AZN) Stock Moves -0.83%: What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) closed the most recent trading day at $66.64, moving -0.83% from the previous trading session.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Eli Lilly's (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide medicines, Mounjaro and Zepbound.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag

by Zacks Equity Research

AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.

GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?

by Zacks Equity Research

We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.

Novo Nordisk (NVO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk's (NVO) sales in fourth-quarter 2023 are expected to have been driven by increased Diabetes and Obesity Care product sales despite pricing pressure in the United States.

Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Astrazeneca (AZN) Laps the Stock Market: Here's Why

by Zacks Equity Research

In the latest trading session, Astrazeneca (AZN) closed at $67.02, marking a +0.63% move from the previous day.

Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.

Pfizer (PFE) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.